{"id":"nanoflu","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NanoFlu uses self-assembling nanoparticles derived from recombinant hemagglutinin (HA) protein to create a highly immunogenic vaccine platform. The nanoparticle structure presents multiple copies of HA antigen in a particulate form, which enhances recognition by the immune system and promotes stronger antibody and T-cell responses compared to traditional inactivated influenza vaccines. This approach aims to provide improved efficacy and broader protection against seasonal influenza.","oneSentence":"NanoFlu is a recombinant nanoparticle-based influenza vaccine that displays hemagglutinin proteins on virus-like particles to stimulate robust immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:16.864Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of seasonal influenza in adults"}]},"trialDetails":[{"nctId":"NCT04120194","phase":"PHASE3","title":"Phase 3 Pivotal Trial of NanoFlu™ in Older Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2019-10-14","conditions":"Influenza, Human","enrollment":2654},{"nctId":"NCT03293498","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)","status":"COMPLETED","sponsor":"Novavax","startDate":"2017-09-18","conditions":"Influenza","enrollment":330},{"nctId":"NCT03658629","phase":"PHASE2","title":"Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults","status":"TERMINATED","sponsor":"Novavax","startDate":"2018-09-24","conditions":"Influenza, Human","enrollment":1375}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Quad-NIV"],"phase":"phase_3","status":"active","brandName":"NanoFlu","genericName":"NanoFlu","companyName":"Novavax","companyId":"novavax","modality":"Biologic","firstApprovalDate":"","aiSummary":"NanoFlu is a recombinant nanoparticle-based influenza vaccine that displays hemagglutinin proteins on virus-like particles to stimulate robust immune responses. Used for Prevention of seasonal influenza in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}